GET DAILY SIGNALSNEXGEL (NXGL) Q3 2026 Earnings Preview: +43% Revenue Growth Expected
Key Takeaways
- NEXGEL is expected to report its third-quarter 2026 results around mid-November 2026, covering the period ended September 30, 2026.
- Wall Street consensus points to revenue of roughly $4.19 million, up about 43% from $2.93 million a year earlier, alongside a continued net loss per share.
- The report is the first full quarter to reflect the company's April 2026 acquisition of Celularity's regenerative biomaterials portfolio, now operating as the BioNX Surgical division.
- In the prior quarter, revenue rose 27.8% year over year to $3.69 million but missed the $4.32 million consensus, while the net loss widened on one-time transaction and integration costs.
- Management's going-concern warning and a thin unrestricted cash position keep liquidity and the path to profitability at the center of investor attention.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for NXGL.
- You can also explore Trending AI Robots to see how automated strategies are navigating current market conditions.
Earnings Context and Why It Matters
NEXGEL develops high-water-content hydrogels used in wound care, medical diagnostics, and consumer cosmetics. This report carries extra weight because it is the first full quarter to reflect the company's acquisition of Celularity's regenerative biomaterials portfolio, now consolidated under the BioNX Surgical division. In my view, investors are watching closely whether new biomaterials revenue can offset softness in consumer-branded products and contract manufacturing while narrowing losses. With the stock having fallen sharply over the past year and management having raised substantial doubt about the company's ability to continue as a going concern, this release is a critical checkpoint for assessing liquidity, integration progress, and any credible path toward sustainable profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Consensus estimates call for third-quarter 2026 revenue of approximately $4.19 million, which would represent year-over-year growth of roughly 43% from the $2.93 million reported in the year-ago quarter. Analysts also expect another net loss per share, reflecting ongoing investment in the BioNX Surgical integration. It is worth noting that analyst coverage remains thin, with a single estimate in the consensus, so these figures should be read with caution.
Recent results set a demanding comparison. In the second quarter of 2026, NEXGEL reported revenue of $3.69 million, up 27.8% year over year but below the $4.32 million consensus. The net loss widened to about $3.6 million as the company absorbed intangible-asset amortization, one-time transaction expenses, and costs tied to a strategic recall of its SilverSeal product. The company has beaten consensus estimates on earnings per share in only a handful of its recent quarters, meaning execution and cost control will be closely scrutinized heading into this report. From what I see, the integration costs remain a key variable.
Market Reaction and Investor Sentiment
Sentiment heading into this report is cautious. NEXGEL's shares have been highly volatile over the past year, trading well below their late-2024 highs as recurring losses, dilution concerns, and the going-concern disclosure weighed on investor confidence. The company has also experienced significant share-count changes, which have contributed to an elevated loss per share on a reported basis and made quarter-to-quarter comparisons harder to interpret.
Following the last earnings release, the stock exhibited a notable post-announcement drift lower, suggesting the market is quick to punish execution shortfalls. Key risk factors ahead of this print include the pace of BioNX revenue ramp, supply-chain constraints in the newly formed surgical division, and any additional capital raises that could dilute existing shareholders. A narrower-than-expected loss or clear evidence of accelerating biomaterials demand would likely be viewed positively, while another revenue miss or fresh liquidity concerns could reignite selling pressure.
Forward Outlook and Key Factors to Monitor
Looking beyond the third-quarter print, the central question is whether the BioNX Surgical division can translate its regenerative biomaterials portfolio into sustainable, higher-margin revenue. Management has pointed to the hospital channel as a meaningful growth opportunity, and the strategic SilverSeal recall was undertaken partly to support that channel's launch. Investors should watch for updates on hospital adoption, gross margin trends, and whether supply-chain constraints ease.
Liquidity remains a defining risk. The company ended its second quarter with limited unrestricted cash and negative working capital, and it has signaled it may need additional debt or equity financing. Any new capital raise, and its terms, will matter as much as the operating results themselves.
Finally, watch for progress on the broader product pipeline, including the partnership with STADA and expansion of consumer-branded offerings. Evidence of cost discipline and a narrowing loss per share toward break-even would be the clearest signals that NEXGEL is converting acquisition-driven top-line growth into a more durable financial footing. I’m watching this closely for signs of stabilization.
AI Tools in My Research Process
One thing that stands out when preparing for earnings like this is how helpful structured screening can be. I often turn to Tickeron’s AI Screener to quickly compare NXGL against peers on metrics such as revenue growth, volatility, and technical patterns. It helps surface comparable small-cap names and puts the upcoming numbers into broader context without hours of manual work. The tool has become a regular part of my workflow for events like this.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NXGL sees MACD Histogram crosses below signal line
NXGL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 29, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 51 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NXGL as a result. In 100 of 116 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
NXGL broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NXGL entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NXGL's RSI Oscillator exited the oversold zone, 23 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +24.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXGL advanced for three days, in 149 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.894) is normal, around the industry mean (4.964). P/E Ratio (-4.730) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.172) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. NXGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement